
India's first gene-edited sheep developed in Kashmir Agricultural university. All you need to know
Researchers at a Kashmir-based Agricultural university have produced India's first gene-edited sheep, marking a historic milestone in the field of animal biotechnology.
The Sher-e-Kashmir University of Agricultural Sciences and Technology (SKUAST) has called it a "ground-breaking scientific achievement".
The edited sheep contains no foreign DNA, distinguishing it from transgenic organisms and paving the way for regulatory approval under India's evolving biotech policy framework, news agency PTI said.
The team of researchers led by Dean Faculty of Veterinary Sciences, SKUAST-Kashmir, Riaz Ahmad Shah achieved the feat after a research of around four years. Shah's team had previously cloned India's first Pashmina goat- 'Noori'- in 2012, a milestone that garnered global acclaim.
"This path-breaking development places India on the global map of advanced genome editing technologies and positions SKUAST-Kashmir at the forefront of reproductive biotechnology research," Shah told PTI, adding, it marks a historic milestone in the field of animal biotechnology.
The gene editing was performed using CRISPR-Cas9 technology and adhered to international biosafety protocols.
Shah said the gene-edited lamb has been modified for the 'myostatin' gene - a regulator of muscle growth. 'By disrupting this gene, muscle mass in the animal is enhanced by nearly 30 per cent, a trait naturally absent in Indian sheep breeds but known in select European breeds like the Texel,' he said.
For now this has been done at research level. 'The technique has multiple applications. We can edit the genes responsible for diseases to produce disease-resistant animals. It can also help in the twinning of animals at birth,' Shah told The Indian Express.
Gene editing, also known as genome editing, is a group of technologies that allow scientists to precisely change an organism's DNA. These technologies enable the addition, removal, or alteration of genetic material at specific locations within the genome.
The development comes on the heels of the recent release of India's first gene-edited rice variety, endorsed by Union Ministry for Agriculture, and further cements India's growing prowess in genomic science, Shah said.
"The introduction of this mutation through gene editing, and not through traditional crossbreeding, represents a technological leap akin to the revolution Artificial Intelligence is driving in the 21st century," he said.
SKUAST-Kashmir vice-chancellor Nazir Ahmad Ganai described the achievement as the birth of a new era in livestock genetics in the country.
"This is not just the birth of a lamb, but the birth of a new era in livestock genetics in India. With gene editing, we have the ability to bring precise, beneficial changes without introducing foreign DNA, making the process efficient, safe, and potentially acceptable to both regulators and consumers," he said.
Through gene editing, the researchers targeted a gene in a sheep variety that helps in boosting its muscle weight and gives heavier, almost 30 per cent more weight than normal sheep.
This is not just the birth of a lamb, but the birth of a new era in livestock genetics in India.
"We have got the offspring from the mother, and one with the mutated gene is distinctly heavier than the non-mutated,' the vice-chancellor said adding that the DNA of the mutated lamb, which is now three months old, will be sent to foreign research labs for further verification.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
an hour ago
- Time of India
Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on to certain exceptions, each party will have the right to commercialise the product traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.


India.com
an hour ago
- India.com
India's Rs 548 crore Space Leap: Shukla rides the Falcon 9 to the ISS
On June 10, 2025, at 5:52 PM IST (8:22 AM EDT), Group Captain Shubhanshu Shukla will lift off to the International Space Station (ISS), becoming the first Indian astronaut since 1984 to undertake such a journey. As the pilot of Axiom Mission 4 (Ax-4), he will fly aboard a SpaceX Crew Dragon spacecraft, launched on a Falcon 9 rocket from NASA's Kennedy Space Center in Florida. After approximately 28 hours of travel, the crew is expected to dock with the ISS by 10:00 PM IST on June 11, 2025. Shukla joins an elite international crew: Commander Peggy Whitson (USA, Axiom Space), and Mission Specialists Sławosz Uznański-Wiśniewski (Poland, ESA) and Tibor Kapu (Hungary, Hunor Programme). The team will spend up to 14 days aboard the ISS, conducting over 60 scientific experiments from 31 countries, including seven from India, such as research on plant growth in microgravity, muscle regeneration, and tardigrade resilience. Born on October 10, 1985, in Lucknow, Shukla is a decorated Indian Air Force test pilot with over 2,000 flight hours. He has undergone rigorous astronaut training in Russia and at SpaceX facilities in the US, and will assist in spacecraft navigation, docking, and emergency procedures during the mission. But beyond his technical role, Shukla carries India's cultural pride into space—bringing along items designed by National Institute of Design (NID) students, performing yoga in microgravity, sharing Indian delicacies like mango nectar and moong dal halwa, and planning live interactions with Indian school children and possibly Prime Minister Narendra Modi. SpaceX has revolutionized space travel economics. While NASA pays around $55 million per seat under its commercial crew program, private clients like Axiom Space are charged $52–55 million per seat, excluding stay-related fees. NASA charges $35,000 per night per astronaut for use of the ISS. India's investment for Shukla's mission seat is around ₹548 crore (approximately $65 million), while the total private mission cost per astronaut can go up to $100 million, including training and logistics. In comparison, Russia's Soyuz costs around $80–86 million per seat, Boeing's Starliner costs about $90 million, and the now-retired Space Shuttle had a cost of approximately $170 million per astronaut. For reference, cargo missions on SpaceX's Dragon cost anywhere between $21,000 and $89,000 per kg, while human missions are far costlier due to added life support and safety systems. Shukla's mission is more than just a spaceflight—it's a symbol of India's return to human space exploration. He carries a special swan named 'Joy', representing wisdom (India), resilience (Poland), and grace (Hungary). The scientific experiments onboard are expected to contribute to India's ambition of establishing a space station by 2035 and support its moon mission goals set for 2047. This mission also strengthens international space ties, especially between India and the US, following commitments made during PM Modi's 2023 visit. In every sense, Group Captain Shubhanshu Shukla's journey aboard the human-rated Falcon 9 rocket is a giant leap for India—both in science and symbolism. With his successful flight, India not only rekindles its human spaceflight legacy after four decades but also sets the stage for greater roles in global space partnerships, cutting-edge research, and inspiration for the next generation of Indian scientists, engineers, and dreamers. —E.O.M (Girish Linganna is an award-winning science communicator and a Defence, Aerospace & Geopolitical is the Managing Director of ADD Engineering Components India Pvt. Ltd., a subsidiary of ADD Engineering GmbH, Germany )


Time of India
2 hours ago
- Time of India
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda HYDERABAD: Dr Reddy's Laboratories has entered into a collaboration and license agreement with Iceland-based biotech player Alvotech for the co-development, manufacturing and commercialiation of a biosimilar of Merck Sharp & Dohme's blockbuster drug Keytruda (pembrolizumab). Keytruda, which is used for the treatment of various types of cancer, clocked sales of over US$29.5 billion in 2024. The collaboration will combine Dr Reddy's and Alvotech's capabilities in biosimilars to speed up the development process and extend the global reach of the biosimilar candidate. As per the agreement, the two companies will share the costs and responsibilities for jointly developing and manufacturing the biosimilar candidate and subject to certain exceptions, each company will have the right to commercialise the product globally, Dr Reddy's said on Thursday. 'The agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide,' said Róbert Wessman, chairman & CEO, Alvotech. Dr Reddy's CEO, Erez Israeli, said the pact demonstrates the company's ability to develop and manufacture high-quality and affordable treatment options for patients worldwide. 'Oncology has been a top focus therapy area for us, and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,' Israeli added. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now